Although BRAF mutation positivity provided a potential therapeutic pathway with BRAF inhibitors (like dabrafenib and vemurafenib) and MEK inhibitors (like trametinib) that block this specific pathway, slowing tumour growth, her frailty and rapid deterioration excluded systemic treatment. Here, BRAF is linked to neoplasm.